Solomon, Isabelle
Amann, Maria
Goubier, Anne
Arce Vargas, Frederick
Zervas, Dimitrios
Qing, Chen
Henry, Jake Y.
Ghorani, Ehsan http://orcid.org/0000-0001-5373-5762
Akarca, Ayse U.
Marafioti, Teresa
Śledzińska, Anna
Werner Sunderland, Mariana
Franz Demane, Dafne
Clancy, Joanne Ruth
Georgiou, Andrew
Salimu, Josephine
Merchiers, Pascal
Brown, Mark Adrian
Flury, Reto
Eckmann, Jan
Murgia, Claudio
Sam, Johannes
Jacobsen, Bjoern
Marrer-Berger, Estelle
Boetsch, Christophe
Belli, Sara
Leibrock, Lea
Benz, Joerg
Koll, Hans
Sutmuller, Roger
Peggs, Karl S.
Quezada, Sergio A. http://orcid.org/0000-0002-9763-1700
Article History
Received: 22 July 2020
Accepted: 28 September 2020
First Online: 9 November 2020
Competing interests
: Two patent applications, WO/2018/167104 and US20190284287, with relevance to this work have been filed by Cancer Research Technology Limited and Tusk Therapeutics, and we declare our relationship with this patent. I.S. F.A.V., S.A.Q., K.S.P., A.G., J.S. and P.M. are named inventors on this patent. F.A.V., S.A.Q., I.S. and K.S.P. receive royalties related to this patent. S.A.Q. is an advisor to TUSK/Roche. M.A., R.F., J.E., C.M., J.S., B.J., L.L., H.K., J.B., S.B., C.B., E.M.-B. and R.S. are employees of Roche, which plans clinical development of the drug. M.A., R.F., J.E., C.M., J.S., B.J., H.K., J.B., S.B., C.B., E.M.-B. and R.S. have shares in the companies to which the patent belongs.